Immunicum AB (publ) (IMMU.ST)

0.4745 +0.0045 (+0.96%) At close: 05:23PM CEST

Immunicum AB (publ)

Västra Trädgårdsgatan 15
Stockholm 111 53
Sweden
46 87 32 84 00
https://www.mendus.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 30

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Erik Manting Ph.D.	Chief Executive Officer	N/A	N/A	1971
Mr. Alex Karlsson-Parra M.D., Ph.D.	Co-Founder & Chief Scientific Officer	1.42M	N/A	1950
Ms. Lotta Ferm	Chief Financial Officer	N/A	N/A	1966

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which completed Phase I clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a preclinical study for NK cell-based therapies. It has an alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel; and the Australasian Leukaemia and Lymphoma Group to expand the clinical development of vididencel as a maintenance treatment for AML. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.

Corporate governance

Immunicum AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.